21220519

Source:http://linkedlifedata.com/resource/pubmed/id/21220519

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0205179, umls-concept:C0205390, umls-concept:C0278883, umls-concept:C1516119
pubmed:issue	7
pubmed:dateCreated	2011-6-27
pubmed:abstractText	The combination of sorafenib, a multikinase inhibitor, and pegylated interferon-?2b (Peg-IFN-?2b) could potentially lead to an improved antitumoral response. Previously, combinations of interferon and sorafenib have been used in renal cell cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b, http://linkedlifedata.com/resource/pubmed/chemical/sorafenib
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1569-8041
pubmed:author	pubmed-author:BeckerJ CJC, pubmed-author:BerkingCC, pubmed-author:DegenAA, pubmed-author:EgbertsFF, pubmed-author:FreyLL, pubmed-author:GarbeCC, pubmed-author:GutzmerRR, pubmed-author:HasselJ CJC, pubmed-author:HauschildAA, pubmed-author:KaehlerK CKC, pubmed-author:LivingstoneEE, pubmed-author:MauckLL, pubmed-author:MohrPP, pubmed-author:RasiAA, pubmed-author:SchadendorfDD, pubmed-author:SchenckFF, pubmed-author:TrefzerUU, pubmed-author:UgurelSS, pubmed-author:WeichenthalMM, pubmed-author:WilhelmTT
pubmed:issnType	Electronic
pubmed:volume	22
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1667-74
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21220519-Adult, pubmed-meshheading:21220519-Aged, pubmed-meshheading:21220519-Aged, 80 and over, pubmed-meshheading:21220519-Antineoplastic Agents, pubmed-meshheading:21220519-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21220519-Antiviral Agents, pubmed-meshheading:21220519-Benzenesulfonates, pubmed-meshheading:21220519-Female, pubmed-meshheading:21220519-Follow-Up Studies, pubmed-meshheading:21220519-Head and Neck Neoplasms, pubmed-meshheading:21220519-Humans, pubmed-meshheading:21220519-Interferon-alpha, pubmed-meshheading:21220519-Male, pubmed-meshheading:21220519-Maximum Tolerated Dose, pubmed-meshheading:21220519-Melanoma, pubmed-meshheading:21220519-Middle Aged, pubmed-meshheading:21220519-Neoplasm Staging, pubmed-meshheading:21220519-Polyethylene Glycols, pubmed-meshheading:21220519-Prospective Studies, pubmed-meshheading:21220519-Pyridines, pubmed-meshheading:21220519-Recombinant Proteins, pubmed-meshheading:21220519-Survival Rate, pubmed-meshheading:21220519-Treatment Outcome, pubmed-meshheading:21220519-Young Adult
pubmed:year	2011
pubmed:articleTitle	Sorafenib and pegylated interferon-?2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
pubmed:affiliation	Department of Dermatology, University of Kiel, Kiel, Germany.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II